For the constellation of neurological disorders known as chemotherapy induced peripheral neuropathy, 17 mechanistic understanding, and treatment remain deficient. Here we present the first evidence in preclinical 18 investigation of rats that chronic sensory neuropathy depends on non-linear interactions between cancer and 19 chemotherapy. Global transcriptional profiling of dorsal root ganglia revealed differential expression, notably in 20 regulators of neuronal excitability, metabolism and inflammatory responses, all of which were unpredictable 21 from effects observed with either chemotherapy or cancer alone. Systemic interactions between cancer and 22 chemotherapy also determined the extent of deficits in sensory encoding and ion channel protein expression 23 by single mechanosensory neurons, with the potassium ion channel Kv3.3 emerging as a potential contributor 24 to sensory neuron dysfunction. These original findings identify novel contributors to peripheral neuropathy, 25 and emphasize the fundamental dependence of neuropathy on the systemic interaction between 26 chemotherapy and cancer. 27 original findings to show that sensory neuropathy depends on complex systemic interactions between cancer 53 and chemotherapy. By combining cancer and chemotherapy, we reproduce the relevant clinical condition in 54 preclinical study of rats to produce the first transcriptional profile of nervous tissue, to discover recurrent 55 metabolic reprogramming and perturbed inflammatory and ion channel processes distinct from the 56 independent effects of cancer or chemotherapy. Parallel codependency is found in novel neuropathic 57 responses of mechanosensory neurons, both in their immunohistochemistry for selected voltage-gated 58 potassium ion channels and in electrophysiological measures of encoding naturalistic stimuli in vivo. 59
Introduction 28
Chemotherapy can achieve high rates of survival in patients with common cancers 1 but often causes severe 29 side effects, including neuropathy, that can limit its use 2-4 . Debilitating sensory disorders, including pain, 30 paraesthesia, and somatosensory loss, reduce quality of life for many patients and can persist for months or 31 years after discontinuing chemotherapy 5-7 . These neurological disorders occur for up to 80% of patients 32 receiving commonly used antineoplastic agents, notably antitubulins and proteasome inhibitors, as well as 33 platinum-based compounds 7, 8 , which are the prescribed adjuvant treatment in 50% of cancer cases 34 worldwide 9,10 . There are no options available for the prevention of sensory disorders and the few available 35 pharmacological treatments that focus on symptomatic management are largely ineffective 11 . Thus, there is an 36 urgent need to better understand the pathogenesis of sensory dysfunction to aid development of mechanism-37 based therapies. 38
Preclinical studies of chronic neuropathy in experimental models of cancer are unavailable, possibly because 39 of presumption that chemotherapy alone is sufficient to explain the neuropathology. A recently published 40 meta-analysis identified 341 preclinical studies of chemotherapy induced neuropathy, and none assessed 41 interaction between chemotherapy and cancer 12 . Omitting cancer from preclinical study produces a 42 fundamental gap in knowledge that may explain why treatments for neuropathic side effects of chemotherapy 43 have been unsuccessful in patients with cancer. Cancerous tumors located outside the nervous system can 44 induce cognitive disability and peripheral nervous system dysfunction independent of chemotherapy, surgery, 45 or co-morbidities 13, 14 . Moreover, cancer provokes dysregulation in immune, metabolic, oxidative and neuronal 46 excitability 15, 16 , all of which are identified as targets through which chemotherapy produces neuropathy 2 . 47
Convergence of cancer and chemotherapy on the same biological processes seems likely to yield non-linear 48 interactions, leading us to hypothesize that clinically relevant neuropathy emerges from codependent acti ons of 49 cancer and chemotherapy. 50
We tested our hypothesis by uncoupling the independent and combinatorial effects of cancer and 51 chemotherapy on sensory neurons in studies of rats that are not feasible in human patients. Here we present 52
Our data present the first evidence that Il6 (IL6) expression levels remain elevated long after treatment 135 cessation without observable morphological changes. We show that codependent neuropathy significantly 136 increases Il6 (IL6) when compared to chemotherapy or cancer alone. In light of IL6's capacity to decrease 137 excitability following chronic exposure 28 , our data suggest that neuronal dysfunction as a result of codependent 138 neuropathy may be expressed as hypo-excitability, in contrast with previous work 7 .
139 Broad dysregulation of neuron transcriptomes 140 We then used gene-set enrichment analysis (GSEA) as a second independent tool to investigate the cellular 141 processes underlying codependent neuropathy. We initially focused on the comparison of Apc WT +OX and 142 Apc Pirc/+ +OX ( Fig. 3a) and Apc Pirc/+ +control and Apc Pirc/+ +OX (Fig. 3b ) and interrogated entire data sets against 143 the Molecular Signatures Database (Extended Data Table 2 ). Two novel conclusions can be drawn from the 144 GSEA findings. First, GSEA independently validated codependencies of cancer and chemotherapy in the DEG 145 identified by transcriptional profiling using paired unsupervised analysis ( Figs. 3a and 3b ). GSEA corroborated 146 downregulation of lipid metabolic pathways (normalized enrichment score (NES)=1.73) and upregulation of 147 glycolytic pathways (NES=−1.94) in Apc Pirc/+ +OX sensory neurons when compared with either chemotherapy 148 ( Fig. 3a ) or cancer alone (Fig. 3b ). Focusing analysis on pathways directly involved in neuronal signaling 149 confirmed dysfunction in peripheral neuron ensheathment in the absence of evidence supporting neuron 150 specific apoptotic response (FDR>0.83) ( Fig. 3a) . Second, GSEA exposed dysregulation of genes relevant to 151 neuronal excitability particularly potassium ion channels and transporters, and others participating in synaptic 152 communication, e.g. SNARE and glutamatergic transmission ( Fig. 3a,b ). Dysregulation of these and other 153 gene sets (e.g. proinflammatory chemokines) was not predicted from the independent effects of cancer or 154 chemotherapy alone. (Fig. 3c,d and Extended Data Table 2 ). Unlike previous studies that consistently report 155 dysregulated voltage-gated sodium channels, we find little evidence of differentially expressed sodium 156 channels or disrupted regulatory pathways 29 . Instead, we find targeted DEG related to potassium ion channels 157 unlike those previously identified. We draw two conclusions from these data. First, ion channel clusters are 158 differentially vulnerable to codependent neuropathy. Second, chronic neuropathy may be mechanistically 159 linked to dysregulation of ion channels distinct from those identified in acute preparations. 160
Taken together, our analyses indicate significant dysregulation of genes and proteins mediating core cellular 161 processes of Apc Pirc/+ +OX sensory neurons. Our integrated transcriptomics and protein level findings confirmed 162 that cancer and chemotherapy effect common processes 15, 30, 31 . Moreover, our findings support our central 163 hypothesis that clinically relevant neuropathy depends on systemic interaction between cancer and 164 chemotherapy by showing for the first time that codependence exacerbates neuropathy and revealing it 165 operates through distinct mechanistic pathways, unpredicted from cancer or chemotherapy alone.
166 Novel ion channel dysfunction in Apc Pirc/+ +OX 167 Sensory deficits, e.g. somatosensory and hearing loss, are commonly reported by patients long after cessation 168 of chemotherapy, but knowledge of the combined effects of cancer and chemotherapy is missing. 169 Mechanosensory systems, e.g. cochlear hair cells, and various somatosensory neurons in skin and muscle are 170 responsible for encoding this information and exhibit deficits following chemotherapy 8 . We therefore next 171 focused on identifying the combined effects of cancer and chemotherapy on a representative member of 172 mechanosensory neurons, called muscle spindles. Muscle spindles share many of the molecular 173 mechanisms 32 underlying mechanotransduction and encoding found in this broad class of sensory neurons 174 (e.g. hair cells 33 , Merkel 34 ). Further, signaling by these neurons encodes sensory features of muscle 175 mechanics necessary for perceiving (proprioception) and coordinating body position and movement, functions 176 which, when impaired, have the potential to explain persistent disorders in patients 35 . We performed targeted 177 analyses of our transcriptome database by querying DEGs identified in Apc Pirc/+ +OX rats compared to all other 178 groups against genes encoding proteins known to be constitutively expressed in mechanosensory neurons that 179 mediate unique contributions to neuronal signaling (Extended Data Fig. 5 ) 32,36,37 . We found no evidence for 180 independent nor combinatorial effects of cancer or chemotherapy at the genetic level ( Fig. 4a and Extended 181 Data) for channels mediating mechanotransduction (e.g. Asic2, Piezo2, ENaCs), signal amplification, and 182 spike encoding (e.g. Scn1a (Nav1.1), Scn8a (Nav1.6), Scn9a (Nav1.7), Cacna1s,-c,-d, -f (Cav1.1-4), Kcnn2 183 (SK2), Kcna1 (Kv1.1)) 184 Next, we performed cell-specific immunohistochemical analyses to test gene-protein correspondence. We 185 found no evidence to suggest dysregulated protein expression nor did evidence emerge to suggest altered 186 protein distributions (Extended Data Figs. 6-8) for most proteins, including those mediating 187 mechanotransduction (ASIC2), signal amplification (Nav1.1, Nav1.6, Nav1.7), spike encoding (Kv1.1), and 188 mechanosensory sensitivity (VGLUT1). These findings demonstrate that many of the molecular mechanisms 189 responsible for mechanotransduction and determining excitability of mechanosensory neurons were preserved 190 in the Apc Pirc/+ +OX rats. These findings narrow the field of candidate mechanisms for which treatment might 191 reasonably restore normal function.
192 Having exhausted examination of proteins known to be expressed in mechanosensory neurons, we extended 193 our search to include ion channels yet to be identified, but known to regulate neuronal signaling in other 194 classes of neurons [38] [39] [40] [41] . As one of the most dysregulated voltage-gated ion channels, Kcnc3 (encoding protein 195 Kv3.3) emerged as a novel candidate ( Fig. 4a , b, Extended Data Fig. 9 ). Pharmacologic and genetic 196 perturbation of Kv3.3 (Kcnc3) impairs neuronal signaling 40,41 and is causally linked to ataxias 42 that are 197 consistent with functional deficits observed in patients with cancer long after cessation of chemotherapy. We 198 then immunolabeled sensory cell bodies in dorsal root ganglia and their receptor endings taken from 199 Apc WT +control with monoclonal antibodies targeting Kv3.3, which revealed the first evidence of this ion channel 200 in all large diameter cell bodies in the dorsal root ganglia that supply mechanosensors ( Fig. 4c Extended Data 201 Fig. 10 ) and endings ( Fig. 4e ). Results of comparison across experimental groups indicate that Kv3.3 202 expression was significantly lower in Apc Pirc/+ +OX compared with Apc WT +control ( Fig. 4d,) , Apc Pirc/+ +control, or 203 Apc WT +OX (Extended Data Fig. 10 ), demonstrating that codependent dysfunction is conserved in cell-type 204 specific protein expression. Moreover, conserved Kv3.3 expression in neuromuscular junctions suggests that 205 Kv3.3 dysfunction was constrained to sensory neurons (Extended Data Fig. 11 ). This is the first evidence 206 implicating Kv3.3 in the development of neuropathy and the first data, to our knowledge, demonstrating a 207 channelopathy persists long after treatment cessation. The capacity of Kv3.3 to drive fast spiking and to 208 enhance transmitter release -processes that are required for mechanotransduction and spike encoding-209 suggests that this ion channel might provide both a potential novel mechanism for the dysfunction of 210 mechanosensory neurons and a potential target for therapy. 211 Apc Pirc/+ +OX neuronal signaling is impaired 212 Next, we examined whether the codependent neuropathy we discovered at gene and protein levels had 213 negative consequences on mechanosensory function in living animals. (Extended Data Fig. 12 ). Applying 214 electrophysiological methods to rats in vivo, we recorded spiking activity from single mechanosensory neurons 215 responding to naturalistic mechanical stimuli ( Fig. 5a ). From these spiking responses, we collected 31 216 measured and derived parameters (average of four trials; n = 11 Apc WT +control, n=19 Apc WT +OX, n=20 217 Apc Pirc/+ +control, n = 10 Apc Pirc/+ +OX; Extended Data Fig. 13 ) from which we extract four functional features 218 encoded by these neurons, sensitivity, dynamic, static, and history-dependent signaling information (Extended 219 Data Fig. 13 ). In Apc WT +control rats, we found that muscle stretch elicited the spiking expected from sensory 220 neurons in normal animals 43 and humans 44 , specifically high frequency initial bursting at stimulus onset, 221 increasing dynamic firing during increasing stimulus, sustained static firing with slow accommodation during 222 the hold phase of stretch (Fig. 5b) , and history-dependent reduction in spike number (Extended Data Fig. 14  223 and Fig. 6h ).
224 We next tested whether Apc Pirc/+ or OX treatment alone induce signaling dysfunction. Although we find 225 transcriptional dysregulation in Apc Pirc/+ +control ( Fig. 1c and Extended Data Fig. 3a ), we found a remarkable 226 degree of concordance with signaling in Apc WT +control ( Fig. 5b ). Apc Pirc/+ +control neuronal signaling displayed 227 comparable sensitivity to stimuli and showed similar static behavior across all neurons (n = 20; Fig. 5b ,c) as 228 the Apc WT +control. We then found that OX treatment of Apc WT rats induced mild signaling deficits that were 229 less pronounced, occurred in a small proportion of neurons (5/19), and were primarily restricted to sensitivity 230 functional clusters (Fig. 5b ,c and Extended Data Fig. 17d ), validating our previous findings of restricted deficits 231 observed in a different strain of healthy rats treated with OX alone 19 .
232 In contrast to the observations in Apc WT +control, Apc WT +OX, or Apc Pirc/+ +control rats, we found drastically 233 impaired neuronal signaling in Apc Pirc/+ +OX rats ( Fig. 5b ). High frequency initial bursting was attenuated four-234 fold and sensitivity to stimuli was reduced by three-fold at both high ( Fig. 5c ) and low velocity stretch (Extended 235 Data Fig.14, 17d ). During dynamic stimuli, we found marked reduction in the number of spikes over both 236 stretch conditions ( Fig. 5c ). Neurons in Apc Pirc/+ +OX rats also failed to sustain firing ( Fig. 5b ). In addition, we 237 observed fewer spikes ( Fig. 5c ) during rapid accommodation immediately preceding signal deletion, despite 238 constant stimulus ( Fig. 5b ). We then simulated naturalistic compensation by subjecting Apc Pirc/+ +OX neurons to 239 repeated trials at 1, 2, and 3x background stimulus (Lo strain) intensity, which failed to completely rescue 240 signaling back to Apc WT +control levels (Extended Data Fig. 16b ,c,d). These data are the first, to our 241 knowledge, to directly demonstrate a damaging functional interaction between the systemic effects of cancer 242 and chemotherapy in sensory neurons in a living animal. While validating our previously findings of signaling 243 deficits in chemotherapy alone 19 , these data indicate that restrictive signaling deficits induced by chemotherapy 244 or cancer alone were insufficient to reproduce the magnitude, direction and number of dysfunctional 245 parameters induced by codependent neuropathy.
246 Dysfunction does not depend on degeneration 247 We next tested whether the impaired neuronal signaling of Apc Pirc/+ +OX neurons might be explained by dying-248 back degeneration of sensory nerve terminals. While the underlying mechanisms for chemotherapy induced 249 neuropathy are not understood, current data identify 'dying-back' axon degeneration as a major pathology in 250 this disorder 45, 46 . Blinded reviewers assessed the structural integrity of sensory afferents and receptor endings 251 immunolabeled against neurofilament protein (NEFH) 37 . We then tested for functional evidence of 252 degeneration by comparing differences in conduction delays, a physical measure of nerve degeneration that is 253 used clinically 26 . Neither histological observation of sensory afferents and receptors ( Fig. 5d ) nor axon 254 conduction tests (Extended Data Fig. 15 ) revealed evidence of dying-back degeneration of sensory nerve 255 terminals (Apc Pirc/+ +OX: 1.41±0.13ms, n=10. Apc WT +control: 1.52±0.14ms, n=11, Extended Data Fig. 15 ). Our 256 findings demonstrate that transcriptional changes we observed for some markers of nerve degeneration ( Fig.  257 3) were insufficient to yield nerve degeneration. While our results indicate selective resistance of 258 mechanosensory neurons in Apc Pirc/+ +OX rats, they are in line with the inconsistency of physical evidence for 259 nerve degeneration reported in clinical studies. 26 Furthermore, superimposed vibration immediately restores 260 portions of static signaling, which further refutes the existence of degeneration's role in signaling disorders 261 (Extended Data Fig. 15 ). Overall, our findings suggest that the structure and core ability of mechanosensory 262 neurons to produce action potentials remain unimpaired by codependent neuropathy and does not depend on 263 dying-back degeneration.
264 Dysfunction depends cancer-OX interaction 265 Data presented in Figure 5 suggests damaging cancer-chemotherapy interactions are conserved in vivo and 266 have consequences in sensory function. In order to assess the extent of interaction quantitatively, we took an 267 unbiased statistical approach by subjecting all neurons (n=60, 240 total trials) from all experimental groups to a 268 machine learning algorithm (linear discriminant (LD) analysis). Our approach reduced complex feature space 269 into canonical variables giving us a high-level understanding of where interaction emerges, without biased 270 feature selection a priori. Our analysis yielded three canonical variables ( Fig. 6a ) that achieved overall 94.7% 271 classification accuracy (Extended Data Fig. 17a ). We then visualized neuronal signaling in the new 3D 272 composite space created by LD1-3 ( Fig. 6a ). By projecting high dimensional parameter and feature data onto a 273 simplified 3D canonical space, statistically significant non-linear interaction between cancer and chemotherapy 274 clearly emerged in the first dimension (LD1; 54.23% proportion of variance; Fig. 6a and Extended Data Fig.  275  17b) . Notably, dysfunction in LD1 induced by the cancer-chemotherapy interaction occurred in the opposite 276 direction to that predicted by independent effects, and its magnitude was amplified greater than their sum ( Fig.  277  6a and Extended Data Fig. 17b, c) . To test the statistical significance of the cancer-chemotherapy interaction, 278 we conducted Bayesian model comparison with full factorial and all restricted models using leave-one-out 279 cross validation. We then quantified and validated each model's predictive performance by computing the 280 expected log predictive densities (ELPD; measure of a model's out-of-sample predictive accuracy in Fig. 6b -281 e) 47 . We found decisive evidence in favor of a model including a cancer-chemotherapy interaction predictor 282 (ELPD diff ≥ 48 SE <8.1; Fig. 6e ). Moreover, our data and generative modeling conclude that codependent 283 interaction ( Fig. 6b-d ) is necessary to accurately and reliability reproduce clinically relevant neuronal signaling 284 deficits observed in Apc Pirc/+ +OX rats ( Fig. 6e ) 285 We then asked which functional clusters are highly enriched in LD1. By examining the discriminant function 286 coefficients, we found that static signaling and sensitivity functional clusters represent a large portion of the 287 explained variance in LD1. These findings suggest the sensitivity and static signaling clusters are most 288 susceptible to codependent neuropathy (Extended Data Fig. 17d ).
289 While dynamic signaling provided relatively modest contributions to LD1 (lower coefficient weights in Extended 290 Data Fig. 17d ), examining the parameter level data allowed us to discover the expression of distinct classes of 291 interactions. Independently, OX and Apc Pirc/+ induce highly conserved (87.5%) opposing effects exclusively 292 within the dynamic functional cluster. We consistently found that Apc Pirc/+ mutation increased and OX treatment 293 decreased dynamic firing. This led us to predict that their combination would nullify dysfunction and 294 approximate Apc WT +control signaling. Instead, we observed opposing interactions that resulted in drastic 295 reduction in dynamic firing properties. By contrast, for history-dependent functional clusters, we found that 296 cancer-chemotherapy interaction emerged exclusively in Apc Pirc/+ +OX neurons, since neither Apc WT +OX nor 297 Apc Pirc/+ +control neurons were disrupted.
298 Taken together, we found that 58% of the neuronal signaling parameters in Apc Pirc/+ +OX rats showed high-299 confidence interaction effects, in that those deficits were greater than those observed in either Apc WT +OX nor 300 Apc Pirc/+ +control rats. Our findings demonstrate that complex systemic perturbations of chemotherapy and 301 cancer result in synergistic interactions for sensitivity signaling characteristics ( Fig. 6f ), opposing interactions 302 for peak firing rate during dynamic signaling (Fig. 6g ), and emergent interactions for history dependent and 303 static signaling characteristics ( Fig. 6h ). In summary, Apc Pirc/+ +OX rats express widespread neuronal signaling 304 dysfunction that targets all functional clusters, was independent of structural or physiologically detected 305 degeneration and were not fully accounted for by a global decrease in sensitivity.
306 Discussion 307 Here we present original evidence that cancer transforms the nature and magnitude of neuropathy induced by 308 chemotherapy. Our preclinical study of rats is the first to compare the neuropathic effects of chemotherapy 309 and cancer, both independently and in combination, currently impractical in human study. These comparisons 310 for global transcriptional analysis of sensory neurons in dorsal root ganglia revealed dysregulation of genes 311 uniquely induced, amplified or suppressed by the combination of cancer and chemotherapy. Codependence 312 was conserved as impaired spike encoding of mechanosensory stimuli and novel ion channelopathy. While 313 the present report is limited to rats, extensive conservation of core molecular and cellular processes across 314 mammalian species 48 , leads reasonable expectation that cancer-chemotherapy codependency extends to 315 humans. All considered, we conclude that inattention to co-dependencies necessarily prevents the 316 development of mechanism-based treatments for sensory neuropathy, which remains unexplained and 317 unabated in patients receiving chemotherapy for cancer. 318 Our transcription analyses expose two potential targets for treating sensorimotor disorders among the 319 debilitating patient symptoms that persist following treatment of various cancers with platinum-based 320 compounds and other antineoplastic agents, e.g. taxanes. Patients display deficits in the spatiotemporal 321 parameters (speed and stride) of walking gait, in control of posture, and in balance relying on 322 proprioception 49,50 . Acknowledging that these disabilities may arise from a variety of lesions in the nervous 323 system, the deficits we observe here in the initial detection and encoding of muscle mechanics would 324 necessarily impair movements and postures and cannot be fully compensated by other senses, e.g. vision.
325 Furthermore, signaling by mechanosensory neurons in rats closely resembles that in human 44 . For these 326 reasons, we assign special attention to depressed signaling by muscle spindles and to the associated 327 decrease in expression of the voltage-gated ion channel Kv3.3 and its gene Kcnc3. Reports that Kcnc3 gene 328 knock out impairs firing responses of neurons and results in ataxia 42 promote this gene and its ion channel as 329 potential contributors to signaling deficits observed in the present study. At this time, we are uncertain about 330 the sufficiency of Kv3.3 channelopathy to explain deficient mechanosensory signaling in cancer treated by 331 chemotherapy. Uncertainty arises in part, because comprehensive understanding of the molecular 332 mechanisms underlying the function of these sensory neurons is lacking, although advanced by our discovery 333 of Kv3.3 in mechanoreceptors of healthy animals. Another candidate target for treating sensorimotor disorders 334 is the inflammatory signaling molecule IL6, shown here to express large increases in both gene and protein 335 expression. As a result of its effect in suppressing neuronal firing behavior 28 IL6 has the potential to explain 336 decreased signaling by mechanosensory neurons. We identify both Kv3.3 and IL6, therefore, as targets 337 worthy of testing for their potential value in treating movement disorders. 338 Our study, being restricted to a single time point following chemotherapy, does not assess the stability of 339 potential treatment targets that emerge from codependent neuropathy. It is reasonable to expect, however, 340 that the codependence undergoes dynamic change. Cancer, presumably also its associated systemic effects, 341 undergoes complex progression as subpopulations of cancer cells differentially resist, adapt, or succumb to 342 chemotherapy. Moreover, biological systems themselves initiate dynamic responses to perturbations. In the 343 nervous system, homeostatic regulation initiates compensatory mechanisms to offset perturbations in neuronal 344 excitability 39 . It is thought provoking in this regard to consider the possibility that the chronic hypoexcitability 345 which follows the acute hyperexcitability 2,45 that develops during chemotherapy reflects the actions of a 346 dysregulated compensatory mechanism. Understanding these non-linear interactions processes and their 347 effects on potential treatment are both challenging and necessary for developing effective cancer treatment. Chemotherapy treatment. OX was injected i.p. once a week (10mg/Kg, 1 ml 5% dextrose in DMSO ) to 87 achieve a cumulative dose of 70 mg/Kg over 7 weeks, which scales to a human dose of 420mg/m2 88 (conversion based on rat body surface area and Km= 6) 6,7 . This dose minimizes nerve degeneration in 89 patients 8,9 . The VC groups received i.p. injection of vehicle (1 ml 5% dextrose in DMSO). Body weight was 90 measured 2x/week, which, combined with regular food monitoring, provided early detection of cancer related 91 cachexia 10 . Throughout treatment, rats were frequently monitored for pain or distress. No individual rat reached 92 set criteria established for early removal from the study, e.g. 20% weight loss, vocalization, failure to drink or 93 groom, severe lethargy, self-mutilation, uncontrollable infection. 94
Animal Groups. To determine the independent and combinatorial influence of cancer and OX on neuronal 95 dysfunction, we included four groups of animals in all experiments based on the F344 genetic background 96 (Apc WT ). Age matched (4 months, tumors detected at 2 months of age) F344 rats were randomly assigned to 97 vehicle control (Apc WT +control) and OX treatment groups (Apc WT +OX). Age matched, male Pirc rats were 98 randomly assigned to VC (Apc Pirc/+ +control) or OX treatment (Apc Pirc/+ +OX) at 4 months of age when fully 99 developed cancer is present 2 . 00 Surgical Procedures. Terminal in vivo experiments were performed 5 weeks after achieving clinically relevant 01 chemotherapy doses, 12 weeks total. They were designed to measure the firing of individual intact sensory 02 neurons in response to physiologically relevant muscle contraction and stretch with electrophysiological 03 techniques. All in vivo procedures are well established in our lab and have been extensively described in 04 previous publications 11-15 ; however, brief descriptions are provided. Rats were deeply anesthetized by 05 inhalation of isoflurane (5% in 100% O2), intubated via a tracheal cannula, then maintained for the remainder of 06 the experiment (up to 12 hours by 1.5-2.5% in 100% O2). Respiratory rate, pCO2, core temperature, pulse rate 07 and pO2 were continuously monitored and maintained by adjusting anesthesia 16 and adjusting heat sources. 08
Dorsal roots (lumbar L4-6), muscles, and nerves in the left hindlimb were prepared for stimulation and/or 09 recording with the rat fixed in a rigid frame at the snout, vertebral bodies, distal tibia, and distal femur (knee 10 angle 120°). Triceps surae muscles (lateral and medial gastrocnemii and soleus) were partially freed of 11 surrounding connective tissue and marked for their resting length (Lo) at ankle angle 90° before their common 12
Achilles tendon was severed at the calcaneus and tied directly to the lever arm of a force-and length-sensing 13 servomotor (model 305B-LR; Aurora Scientific). Triceps surae nerves were loosely positioned in continuity on a 14 unipolar silver stimulating electrode, and all other hindlimb nerves including common peroneal, sural, and 15 posterior tibial nerves were crushed to reduce extraneous neuronal activity. Dorsal rootlets were carefully freed 16 in continuity from overlying connective tissue and supported on bipolar hook electrodes positioned close to the 17 rootlet's entry into the dorsal spinal cord. Exposed tissues were covered with warm mineral oil in pools formed 18 by attaching the edges of severed skin to the recording frame. 19
In vivo Intracellular Recording. Dorsal rootlets positioned in continuity on bipolar recording electrodes were 20 selected for sampling sensory neurons when they produced robust action potential activity in response to both 21 electrical stimulation of triceps surae nerves and stretch of triceps surae muscles. Individual axons penetrated 22 in these rootlets by glass micropipettes (~30 MΩ filled with 2 M K+ acetate) were selected for study when 23 electrical stimulation of triceps surae nerves produced orthodromic action potentials that were readily 24 resolvable and had conduction delay of <2ms. Continuous intracellular recordings from sensory neurons we 25 acquired with Spike2 software (version 8.02). Neurons were first classified on the basis of their responses to stimuli, e.g., muscle twitch contraction and vibration, and second to characterize the afferents' sensory 27 encoding of a range of (naturalistic) physiologically meaningful mechanical events. Sensory neurons were 28 classified on the basis of binary scoring of three criteria previously described by our lab 15 and in the cat 17 . 29 Sensory neurons were classified as Ia by their perfect entrainment to 1-s bouts of high-frequency, small-30 amplitude vibration (100Hz, 80 µm), pause in firing during rising twitch force response (muscle shortening), 31 and by responding with an initial burst of high-frequency firing (>100 pulses per second (pps)) at the onset of 32 muscle stretch. Two stretch paradigms were used to characterize the firing responses of afferents to 33 physiologically relevant mechanical stimuli. Stretches were delivered by the servomotor to triceps surae 34 muscles, which were not engaged in active contraction. In both paradigms, triceps surae muscles were 35 stretched by 3 mm from Lo (7% strain) (Dashed vertical line marks the onset of muscle stretch Fig. 5 
and 36
Extended Data Figure 13-16 ). Ramp-hold-release stretches tested afferent encoding of both fast dynamic 37 (20mm/s, 47% strain rate) and static stimuli; successive triplets of triangular stretch tested slow (4mm/s, 9% 38 strain rate) dynamic and activity-dependent encoding in dynamic stretch known to be influenced by recent 39 signaling history 12 . Strains and strain-rates fall within values expected for animals engaged in normal activities 40 e.g. locomotion 18 , and have been previously used in our lab and others 12, 15, 17, 19 . 41 Tissue Collection. At the conclusion of data collection, rats were overdosed with isoflurane inhalation (5%) 42 then immediately transcardially perfused with cold vascular rinse (0.01 M phosphate buffer with 0.8% NaCl, 43 0.025% KCl, and 0.05% NaHCO3, pH 7.4) followed by room temperature fixative (2% paraformaldehyde in 0.1 44 M phosphate buffer, pH 7.4). Muscles and dorsal root ganglia were quickly dissected and post-fixed for one 45 hour in the same fixative at room temperature. After a brief wash in a 0.1 M PBS, tissues were incubated in 0.1 46 M PBS containing 20% sucrose at 4°C overnight for cryoprotection. Three to four animals from each of four 47 groups were selected for whole-transcriptome analysis alone and did not undergo further analysis. Surgical 48 preparation to expose the lumbar spinal cord took place as described above. Dorsal root ganglia (DRG) from 49 the lumbosacral (L5-S2) spinal cord were surgically removed (4-6 per animal), washed with sterile saline and 50 immediately flash frozen (fresh) in 2-methylbutane (isopentane) pre-chilled in liquid nitrogen. DRG were then 51 stored at -80°C for further analysis (see below). After DRG removal, colonic tumors from Apc Pirc/+ and Apc Pirc/+ 52 +OX rats were dissected and counted prior to post fixation for immunohistochemical analysis Immunohistochemistry and Imaging. Detail immunohistochemistry procedures have been previously 54 described 20 . Briefly, 50-µm thick sections of skeletal muscles, DRGs, and tumors were cut using a Cryostat 55 (Leica). Tissues sections from all treatment groups were processed simultaneously. All tissue sections were 56 incubated overnight in primary antibodies diluted in blocking buffer (5% normal goat serum, 0.3% Triton100 in 57 PBS). The primary antibodies used were as follow: rabbit polyclonal anti-NaV1.6 (ASC-58 009, Alomone Laboratories, 1:200), rabbit polyclonal anti-NaV1.1 (ASC-001, Alomone Laboratories, 1:300), 59 rabbit polyclonal anti-NaV1.7 (ASC-008, Alomone Laboratories,1:100), rabbit polyclonal anti-Kv3. Apc Pirc/+ +OX group) global transcriptional expression data sets were generated in this study. Raw mRNA 78 expression data were processed using Affymetrix Expression Console (EC) software Version 1.4. Raw data 79 probes were normalized using SST-RMA algorithm. Differentially expressed genes (DEG) were determined 80 through a linear fixed effects model (limma 22,23 ) with a robust empirical Bayes (eBayes) framework 24 to 81 moderate the residual variances (1.5 fold change and FDR <1% for multiple test correction across contrasts) 82 22, 23 . This has the effect of increasing the effective degrees of freedom by which gene-wise variances are 83 estimated. This approach reduces the number of false positives for genes with small variances and improves 84 power to detect DEG with larger variances 25 . In effect, this technique allows the borrowing of information 85 across genes to gain statistical power. 86
Unsupervised multivariate analysis. DEGs were subjected to paired multivariate analysis to discover high-87 level data structure. By serially linking two powerful analytic techniques, Principal Components Analysis (PCA) 88 driven Hierarchical clustering, we stabilize clustering performance and reduced dimensionality to tractably few 89 continuous variables containing the most important information on which clustering algorithms are focused 90 which leads to a better clustering solution 26, 27 . PCA and visualization was applied to DEGs with the factoextra 28 91
and FactoMineR 26 packages. PCs capturing high-level structure were then employed to drive hierarchical 92 clustering. Hierarchical clustering and heatmaps were visualization of the data were generated with heatmap.2 93 command within the gplots package 29 in the R environment (3.5.0) 30 . Hierarchical-clustering, using the ward.D2 94 method 31 were applied to the eBayes-filtered gene set to obtain unsupervised visualization of the gene clusters 95 coordinately expressed among the different experimental groups. Prior to hierarchical clustering, genes were 96 de-meaned and standardized across the samples to a mean of zero and an s.d. of 1; z values were then used 97 for clustering. Subclusters were derived using the R function cutree 32 . 98
Pathway and Gene Set Enrichment Analysis. Hypergeometric testing was conducted on subclusters of 99 named genes using DAVID (Database for Annotation, Visualization, and Integrated Discovery) and g:Profiler to 00 pinpoint significantly enriched pathways or gene ontology terms 33,34 . We increase statistical power by 01 hypergeometric testing on subclusters which separates co-regulated (up or down) probe sets 35 . All biological 02 processes with adjusted P < 0.05 were considered significantly enriched. g:Profiler 3-500 (min-max) Benjamini 03
Hochberg FDR correction intersection terms (2) only annotated genes were searched. 04
Parallel identification of pathways significantly enriched in Apc WT +OX, Apc Pirc/+ +control, and Apc Pirc/+ +OX 05 sensory neurons, as compared with Apc WT +control neurons, was performed by GSEA (gene-set enrichment 06 analysis). GSEA enables us to uncover novel sets of functionally related genes by focusing on all detected 07 (above-background) genes. GSEA is unbiased and more sensitive, thus allowing for the detection of even 08 subtle enrichment signals. GSEA was also used to compare our gene-expression profiles with those of 09 previously published, related studies. To this end, we used the Molecular Signature Database v 6.2 (C2-CP: 10 canonical pathways; C3-MIR: microRNA targets; C3-TFT: transcription factor targets; C5-BP: GO biological 11 process; C5-CC: GO cellular component; C5-MF: GO molecular function C7: immunologic signatures gene 12 sets) with the permutation type set to 'gene set,' 15-500 (min-max), to calculate statistical significance, as 13 suggested for fewer than seven replicates; default settings were applied to all the other options. GSEA 14 contrasts were visualized as networks (enrichment maps) using the EnrichmentMap (version 3.1.0) 36 plugin in 15 the Cytoscape software (version 3.7.0) 37 . For GSEA, a false discovery rate (FDR) of <0.2 was considered 16 statistically significant. . Dynamic and static phases of naturalistic stimuli indicated by dark grey (150 ms duration after stretch command onset) and light grey (1 s duration after the dynamic phase) bars. c, Neuronal spiking parameters (n=31 averaged from four trials in each neuron, four shown from fast ramp stimulus) representing different features of sensory stimulus (Apc WT +control (n = 11), Apc WT +OX (n = 19), Apc Pirc/+ (n = 20) and Apc Pirc/+ +OX (n = 10)): mean initial burst frequency (pulses per second [pps]) signaling stretch onset; the number of spikes during dynamic sensory stimulation (shown as a dark grey bar in b); the number of spikes during static sensory stimulation (shown as a light grey bar in b); sensitivity assessed as the inverse of latency to stimulus detection (ms -1 ), i.e. lower sensitivity corresponds to longer latency and higher threshold. d, Confocal image of a neurofilament heavy-chain (NEFH, in green) with immunolabeling of the terminal axon and receptor structure in Apc WT +control, Apc WT +OX, Apc Pirc/+ +control, and Apc Pirc/+ rats. Scale bar, 15 μm. indicates statistically significant differences between experimental groups as empirically derived from hierarchical Bayesian model (stan_glm): 95% highest density intervals do not overlap between groupwsie contrasts. Data presented as mean±s.e.m. Black line illustrates experimentally observed mean LD1 score. Predictive accuracy was measured by calculating expected log predictive density (ELPD) for each model and benchmarked off of the highest performing model. ELPD ( ) indicates difference from optimal model. Negative models represent worse predictive performance. f, Sensitivity assessed as the inverse of latency to stimulus detection (mm -1 ), i.e. lower sensitivity corresponds to longer latency and higher threshold. g, Peak firing rate (pps) achieved during the dynamic sensory stimulus (shown as dark grey bar in Fig. 5b ). h, change in dynamic spike number in successive, slow stretch dynamic sensory stimulus (see Methods and Extended Data Fig. 9 ) and mean firing rate (pps) achieved during the static sensory stimulus (shown as light grey bar in Fig. 5b ). Recordings were analyzed from Apc WT +control (n = 11), Apc WT +OX (n = 19), Apc Pirc/+ (n = 20) and Apc Pirc/+ +OX (n = 10) in b-g, * indicates statistically significant differences between experimental groups as empirically derived from hierarchical Bayesian model (stan_glm): 95% highest density intervals do not overlap between groupwsie contrasts. Arrows in f-h indicate direction and significant differences from Apc WT +control. Circles with slashes indicated no difference predicted for color-coded group. Data presented as mean±s.e.m. 
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